S100A11对宫颈癌患者预后评估的价值  

Prognostic evaluation value of S100A11 protein in patients with cervical carcinoma

作　　者：张静[1] 王丹 徐克友[1] Zhang Jing;Wang Dan;Xu Keyou(Department of Medical Oncology,Zhoukou Central Hospital,Zhoukou Henan 466000,China)

机构地区：[1]河南省周口市中心医院肿瘤内科,河南周口466000

出　　处：《保健医学研究与实践》2023年第11期78-83,共6页Health Medicine Research and Practice

摘　　要：目的探讨宫颈组织S100钙结合蛋白(S100A11)表达及血清S100A11水平与宫颈癌病理特征的相关性及预测宫颈癌预后的价值,以期为临床治疗提供参考。方法选择2017年8月—2020年8月于河南省周口市中心医院确诊的80例宫颈癌患者为宫颈癌组,另选择在河南省周口市中心医院确诊为良性宫颈病变的50例患者为良性组。检测所有患者宫颈组织S100A11表达及血清S100A11水平差异,分析宫颈组织S100A11表达与宫颈癌病理特征的相关性。根据宫颈癌组患者随访24个月的临床结局分为死亡组和存活组,对比2组患者宫颈组织S100A11表达差异及血清S100A11水平差异,并分析宫颈组织S100A11阳性表达与阴性表达患者的平均生存时间、血清S100A11水平对宫颈癌患者预后的预测价值。结果宫颈癌组患者宫颈组织中S100A11阳性率为78.75%(63/80),高于良性组的20.00%(10/50),同时宫颈癌组患者的血清S100A11水平高于良性组,差异均具有统计学意义(P<0.05)。Ⅲ+Ⅳ期、中低分化、出现淋巴结转移以及浸润深度>1/2的宫颈癌患者组织S100A11表达阳性率显著高于I+II期、高分化、未出现淋巴结转移、浸润深度≤1/2的患者,差异均具有统计学意义(P<0.05)。Ⅲ+Ⅳ期、出现淋巴结转移以及浸润深度>1/2的宫颈癌患者血清S100A11水平高于Ⅰ+Ⅱ期、未出现淋巴结转移、浸润深度≤1/2的患者,差异均具有统计学意义(P<0.05)。随访24个月后,宫颈癌患者中死亡26人,存活54人。死亡组患者的宫颈组织S100A11阳性率为96.15%(25/26),高于存活组的70.37%(38/54),差异有统计学意义(P<0.05)。同时死亡组患者的血清S100A11水平也高于存活组患者,差异具有统计学意义(P<0.05)。随访显示,S100A11表达阳性患者的平均生存时间为(13.26±2.65)个月,低于S100A11表达阴性患者的(15.65±3.01)个月,差异有统计学意义(P<0.05)。ROC曲线分析结果显示,血清S100A11评估宫颈癌患者预后的AUObjective This study aims to explore the correlation between S100 calbindin(S100A11)expression in cervical tissue,serum S100A11 levels,pathological features of cervical carcinoma,and the predictive value for cervical carcinoma prognosis,providing evidence for clinical treatment.Methods Eighty patients with cervical cancer who were diagnosed in Zhoukou Central Hospital from August 2017 to August 2020 were selected as the cervical cancer group,and another 50 patients who were diagnosed with benign cervical lesions in the hospital were selected as the benign group.S100A11 expression in cervical tissues and serum S100A11 levels were detected in all patients,and the correlation between S100A11 expression in cervical tissues and pathological features of cervical cancer was analyzed.Following the clinical outcomes of patients with cervical cancer who were followed up for 24 months,the patients were allocated to the death group and survival group.The differences in S100A11 expression in cervical tissue and serum S100A11 levels between the two groups were compared,and the average survival time of patients with positive and negative S100A11 expression in cervical tissue and the prognostic value of S100A11 in serum for patients with cervical cancer were analyzed.Results The positive rate of S100A11 in the cervical cancer group was higher than that in the benign group[78.75%(63/80)vs.20.00%(10/50)].The serum S100A11 level in the cervical cancer group was significantly higher than that in the benign group(P<0.05).The positive rate of S100A11 protein expression in cervical cancer patients with stage Ⅲ+Ⅳ,moderately and poorly differentiated,lymph node metastasis and depth of invasion>1/2 was significantly higher than that in patients with stage Ⅰ+Ⅱ,well-differentiated,absent of lymph node metastasis,and depth of invasion≤1/2(P<0.05).Serum S100A11 levels were significantly higher in cervical cancer patients with stage Ⅲ+Ⅳ,lymph node metastasis,and depth of invasion>1/2 than in patients with stage Ⅰ+Ⅱ,no lymph n

关 键 词：S100钙结合蛋白 宫颈癌 病理特征 预后评估 

分 类 号：R711.74[医药卫生—妇产科学]